Results 241 to 250 of about 606,321 (264)

Linkage and retention in care and the time to HIV viral suppression and viral rebound – New York City

AIDS Care, 2014
The success of antiretroviral therapy (ART) as treatment for the individual patient and as prevention requires the achievment and maintenance of human immunodeficiency virus (HIV) viral suppression. Linkage to and retention in care are required for access to ART.
McKaylee, Robertson, Fabienne, Laraque, Heather, Mavronicolas, Sarah, Braunstein, Lucia, Torian   +4 more
openaire   +2 more sources

Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression?

AIDS, 2008
We investigated whether previous treatment interruptions are associated with a raised risk of viral rebound in individuals who have attained virological suppression.All patients achieving an undetectable viral load while on therapy were followed until viral rebound or the time of the last viral load.
Loveleen K, Bansi, Andrew A, Benzie, Andrew N, Phillips, Simon, Portsmouth, Teresa, Hill, Clifford, Leen, Achim, Schwenk, Margaret, Johnson, Jane, Anderson, Richard, Gilson, Philippa, Easterbrook, Brian, Gazzard, Martin, Fisher, Chloe, Orkin, Kholoud, Porter, Deenan, Pillay, Graham P, Taylor, John C, Walsh, Caroline A, Sabin   +18 more
openaire   +2 more sources

Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failures

AIDS, 2007
We investigated whether the rate of viral rebound decreases with increasing duration of viral suppression and, if so, whether rebound rates in patients previously failing antiretroviral regimens ultimately decline to levels as low as those seen in patients who have never experienced virological failure.All patients from the UK CHIC Study (n = 21 256 ...
Benzie, A A, Bansi, L K, Sabin, C A, Portsmouth, S, Hill, T, Johnson, M, Gilson, R, Easterbrook, P, Gazzard, B, Fisher, M, Orkin, C, Dunn, D, Delpech, V, Taylor, G P, Walsh, J C, Phillips, A N   +15 more
openaire   +3 more sources

Absence of viral rebound after treatment of HIV-infected patients with didanosine and hydroxycarbamide

Lancet, The, 1997
Baseline CD4 count was normal in both patients, except that patient B had a below-normal percentage relative to total lymphocytes. From day 360, both patients remained within normal ranges (table). Plasma RNA was positive at baseline (patient A: 676 copies/mL; patient B: 1120 copies/mL), became undetectable by day 360 and remained undetectable after 12
Jean-Marie Seigneurin, D Peyramond, Farid Hamedi-Sangsari   +2 more
exaly   +3 more sources

Predictors of postpartum viral load rebound in a cohort of HIV‐infected Brazilian women

International Journal of Gynecology & Obstetrics, 2009
AbstractObjectiveTo assess the postpartum viral load of HIV‐infected women treated with potent antiretrovirals (ARVs) during pregnancy, and look for predictors of viral load rebound.MethodsOf 112 women who took potent ARVs during pregnancy, 60 took them as prophylaxis to prevent mother‐to‐child transmission of HIV.
Ines Katerina, Cavallo, Fabiana Maria, Kakehasi, Beatriz Amélia, Andrade, Ana Cristina, Lobato, Regina Amélia, Aguiar, Jorge Andrade, Pinto, Victor Hugo, Melo   +6 more
openaire   +2 more sources

Modelling HIV viral rebound using non‐linear mixed effects models

Statistics in Medicine, 2002
Abstract Individuals infected with the human immunodeficiency virus type 1 (HIV‐1) who initiate antiretroviral therapy typically experience a marked decline in concentrations of HIV‐1 RNA in plasma. Often, however, viral rebound occurs within the first year of treatment and this rebound may be associated with resistance to antiretroviral therapy.
Anthony P, Fitzgerald, Victor G, DeGruttola, Florin, Vaida   +2 more
openaire   +2 more sources

Methods for Meta-Analysis and for Modeling HIV Viral Rebound

2021
In Chapter 1, we develop methods for random-effects meta-analysis of combined outcomes. In clinical practice, treatment decision-making typically depends on an overall assessment of outcomes balancing benefits in various domains and potential risks. When individual patient data (IPD) are available from all studies, combined outcomes can be calculated ...
openaire   +1 more source

The source of HIV viral rebound during antiretroviral therapy interruption

2023
Antiretroviral therapy (ART) effectively suppresses HIV-1 replication. However, HIV-1 rebounds when ART is interrupted due to the persistence of HIV-1 proviruses in CD4+ T cells during suppressive ART. We performed an extensive genetic characterisation of HIV-1 to investigate the cellular and viral mechanisms contributing to this viral rebound.
openaire   +1 more source

Increased Proviral DNA in Circulating Cells Correlates with Plasma Viral Rebound in Simian Immunodeficiency Virus-Infected Rhesus Macaques after Antiretroviral Therapy Interruption.

Journal of Virology, 2021
Luis Montaner, Ronald S Veazey, Widade Ziani   +2 more
exaly  

A flexible nonlinear mixed effects model for HIV viral load rebound after treatment interruption

Statistics in Medicine, 2020
Rui Wang, Cathy Shyr, Ronald Bosch
exaly